[1] DURANTE-MANGONI E,ZARRILLI R.Global spread of drug resistant Acinetobacter baumannii:molecular epidemiology and management of antimicrobial resistance[J].Future Microbiol,2011,6(4):407-422.
[2] XU T,XIA W,RONG G,et al.A 4-year surveillance of antimicrobial resistance patterns of Acinetobacter baumanni in a university-affiliated hospital in China[J].J Thorac Dis,2013,5(4):506-512.
[3] 胡付品,朱德姝,汪复.2011年中国CHINET细菌耐药性监测[J].中国感染与化疗杂志,2012,12(5):321-329.
[4] LEMOSE V,DELAHOZ Z P,ALVIS N,et al. Impact of carbapenem resistance on clinical and economic outcomes among patients with Acinetobacter baumannii infection in Colombia[J]. Clin Microbiol Infect, 2014,20(2):174-180.
[5] 蒯守刚,邵海枫,王卫萍,等.耐碳青酶烯类肠杆菌科细菌的耐药机制研究[J].中华医院感染学杂志,2010,22(20):3441-3444.
[6] DAVIES T A,QUEENAN A M,BRIAN J.Morrow Longitudinal survey of carbapenem resistance and resistance mechanisms in Enterobacteriaceae and non-fermenters from the USA in 2007-09[J].J Antimicrob Chemother,2011,66(10):2298-2307.
[7] CONSALES G,GRAMIGNI E,ZAMIDEI L,et al.A multidrug-resistant Acinetobacter baumannii outbreak in intensive care unit:antimicrobial and organizational strategies[J].Crit Care,2011,26(5):453-459.
[8] 段缓,何先弟.耐碳青霉烯鲍曼不动杆菌感染的原因分析及护理对策[J].中华全科医学,2010,8(2):254-255.
[9] PELEG A Y,SEIFERT H,PATERSON D L. Acinetobacter baumannii:emergence of a successful- pathogen[J].Clin Microbiol Rev,2008,21(3):538-582.
[10] NEONAKIS I K,SPANDIDOS D A,PETINAKI E.Confronting multidrug-resistant Acinetobacter baumannii:a review[J].Int J Antimicrob Agents,2011,37(2):102-109.
[11] PEI G,MAO Y,SUN Y. In vitro activity of minocycline alone and in combination with cefoperazone-sulbactam against carbapenem-resistant Acinetobacter baumannii[J].Microb Drug Resist,2012,18(6):574-577. |
